Literature DB >> 22008766

Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.

C Kabali1, C F von Reyn, D R Brooks, R Waddell, L Mtei, M Bakari, M Matee, K Pallangyo, R D Arbeit, C R Horsburgh.   

Abstract

SETTING: The World Health Organization recommends the use of isoniazid preventive therapy (IPT) for human immunodeficiency virus (HIV) infected patients with a positive tuberculin skin test (TST). However, due to concerns about the effectiveness of IPT in community health care settings and the development of drug resistance, these recommendations have not been widely implemented in countries where tuberculosis (TB) and HIV co-infection is common.
OBJECTIVE: To evaluate the effectiveness of IPT on survival and TB incidence among HIV-infected patients in Tanzania.
DESIGN: A cohort study nested within a randomized trial of HIV-infected adults with baseline CD4 counts of ≥ 200 cells/μ l was conducted to compare survival and incidence of active TB between TST-positive subjects who did or did not complete 6 months of IPT in the period 2001-2008.
RESULTS: Of 558 TST-positive subjects in the analytic cohort, 488 completed 6 months of IPT and 70 did not. Completers had a decrease in mortality compared to non-completers (HR 0.4, 95%CI 0.2-0.8). However, the protective effect of IPT on the incidence of active TB was non-significant (HR 0.6, 95%CI 0.3-1.3).
CONCLUSION: Completion of IPT is associated with increased survival in HIV-infected adults with CD4 counts ≥ 200 cells/μ l and a positive TST.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008766     DOI: 10.5588/ijtld.10.0788

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  12 in total

1.  Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Barudi Mosimaneotsile; Oaitse I Motsamai; Nong Shang; Charles E Rose; James Shepherd
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

2.  Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.

Authors:  B Maharaj; T N Gengiah; N Yende-Zuma; S Gengiah; A Naidoo; K Naidoo
Journal:  Int J Tuberc Lung Dis       Date:  2017-05-01       Impact factor: 2.373

3.  The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.

Authors:  Lelisa Fekadu Assebe; Hailemariam Lemma Reda; Alem Desta Wubeneh; Wondwossen Terefe Lerebo; Saba Maria Lambert
Journal:  BMC Public Health       Date:  2015-04-10       Impact factor: 3.295

Review 4.  Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis.

Authors:  Tendesayi Kufa; Tonderai Mabuto; Evans Muchiri; Salome Charalambous; Dominique Rosillon; Gavin Churchyard; Rebecca C Harris
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

5.  Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis.

Authors:  Isabel Yan; Eran Bendavid; Eline L Korenromp
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

6.  Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe.

Authors:  K C Takarinda; R C Choto; A D Harries; T Mutasa-Apollo; C Chakanyuka-Musanhu
Journal:  Public Health Action       Date:  2017-03-21

7.  Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.

Authors:  Kesetebirhan Delele Yirdaw; Degu Jerene; Zewdu Gashu; M E Edginton; Ajay M V Kumar; Yohannes Letamo; Beniam Feleke; Alula M Teklu; Solomon Zewdu; Bill Weiss; Andrea Ruff
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

8.  Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.

Authors:  D Thindwa; P MacPherson; A T Choko; M Khundi; R Sambakunsi; L G Ngwira; T Kalua; E L Webb; E L Corbett
Journal:  Int J Tuberc Lung Dis       Date:  2018-03-01       Impact factor: 2.373

9.  Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.

Authors:  C Padmapriyadarsini; L Sekar; Devarajulu Reddy; Anandha Chitra; N Poornagangadevi; M Selvaraj; P K Bhavani; S N Mothi; K Nandagopal; S Vennila; M Tamizhselvan; J Maheshmanisha; Upasna Agarwal; B B Rewari; Soumya Swaminathan
Journal:  Indian J Med Res       Date:  2020-12       Impact factor: 2.375

10.  Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study.

Authors:  Tesfay Mehari Atey; Helen Bitew; Solomon Weldegebreal Asgedom; Asrat Endrias; Derbew Fikadu Berhe
Journal:  AIDS Res Treat       Date:  2020-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.